# Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

> **NCT02555683** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 894 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** QAW039
- **DRUG:** QAW039
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02555683
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-11
- **Primary completion:** 2019-10-21
- **Final completion:** 2019-11-04
- **Target enrollment:** 894 (ACTUAL)
- **Last updated:** 2020-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555683, "Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02555683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*